A Self-Biomineralized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice.
A Self-Biomineralized Novel Adenovirus Vectored COVID-19 Vaccine for Boosting Immunization of Mice.
复制标题
DOI：
10.1007/s12250-021-00434-3
复制
发表时间：
2021-10
影响因子：
5.5
通讯作者：
Li C
中科院分区：
文献类型：
--
作者：
Luo S;Zhang P;Zou P;Wang C;Liu B;Wu C;Li T;Zhang L;Zhang Y;Li C
SARS-CoV-2已在全球造成380多万人死亡，几种类型的COVID-19疫苗被紧急批准使用，包括腺病毒载体疫苗。然而，热不稳定性和预先存在的免疫力限制了它的广泛应用。为了克服这些障碍，我们构建了一个自生物矿化腺病毒载体COVID-19疫苗（Sad 23 L-nCoV-S-CaP），在生理条件下，在携带SARS-CoV-2刺突蛋白（S）全长基因的Sad 23 L载体的基础上产生一个磷酸钙矿物外壳（CaP）。检测了该Sad 23 L-nCoV-S-CaP疫苗的结构、热稳定性、免疫原性和避免预先存在的免疫问题的特征。在热稳定性试验中，Sad 23 L-nCoV-S-CaP可在4 °C下储存超过45天，在26 °C下储存超过8天，在37 °C下储存约2天。此外，Sad 23 L-nCoV-S-CaP诱导了更高水平的S特异性抗体和T细胞应答，并且不受预先存在的抗Sad 23 L免疫的影响，表明其可以用作Sad 23 L-nCoV-S引发疫苗的加强免疫。用Sad 23 L-nCoV-S-CaP疫苗加强分别诱导105.01抗S1、104.77抗S2结合抗体、103.04假病毒中和抗体（IC 50）的高滴度和IFN-γ（1466.16 SFC/106细胞）对S肽的稳健T细胞应答。综上所述，COVID-19疫苗Sad 23 L-nCoV-S-CaP的自身生物矿化提高了疫苗效力，可用于预防人类SARS-CoV-2感染的初免-加强方案。在线版本包含补充材料，可通过10.1007/s12250-021-00434-3获得。
SARS-CoV-2 has caused more than 3.8 million deaths worldwide, and several types of COVID-19 vaccines are urgently approved for use, including adenovirus vectored vaccines. However, the thermal instability and pre-existing immunity have limited its wide applications. To circumvent these obstacles, we constructed a self-biomineralized adenovirus vectored COVID-19 vaccine (Sad23L-nCoV-S-CaP) by generating a calcium phosphate mineral exterior (CaP) based on Sad23L vector carrying the full-length gene of SARS-CoV-2 spike protein (S) under physiological condition. This Sad23L-nCoV-S-CaP vaccine was examined for its characteristics of structure, thermostability, immunogenicity and avoiding the problem of preexisting immunity. In thermostability test, Sad23L-nCoV-S-CaP could be stored at 4 °C for over 45 days, 26 °C for more than 8 days and 37 °C for approximately 2 days. Furthermore, Sad23L-nCoV-S-CaP induced higher level of S-specific antibody and T cell responses, and was not affected by the pre-existing anti-Sad23L immunity, suggesting it could be used as boosting immunization on Sad23L-nCoV-S priming vaccination. The boosting with Sad23L-nCoV-S-CaP vaccine induced high titers of 105.01 anti-S1, 104.77 anti-S2 binding antibody, 103.04 pseudovirus neutralizing antibody (IC50), and robust T-cell response of IFN-γ (1466.16 SFCs/106 cells) to S peptides, respectively. In summary, the self-biomineralization of the COVID-19 vaccine Sad23L-nCoV-S-CaP improved vaccine efficacy, which could be used in prime-boost regimen for prevention of SARS-CoV-2 infection in humans. The online version contains supplementary material available at 10.1007/s12250-021-00434-3.
登录
查看更多内容
Chadox1 NCOV-19疫苗可防止恒河猕猴中的SARS-COV-2肺炎。
影响因子：
64.8
作者：
van Doremalen N;Lambe T;Spencer A;Belij-Rammerstorfer S;Purushotham JN;Port JR;Avanzato VA;Bushmaker T;Flaxman A;Ulaszewska M;Feldmann F;Allen ER;Sharpe H;Schulz J;Holbrook M;Okumura A;Meade-White K;Pérez-Pérez L;Edwards NJ;Wright D;Bissett C;Gilbride C;Williamson BN;Rosenke R;Long D;Ishwarbhai A;Kailath R;Rose L;Morris S;Powers C;Lovaglio J;Hanley PW;Scott D;Saturday G;de Wit E;Gilbert SC;Munster VJ
通讯作者：
Munster VJ
构建高病毒滴度的新型猿猴腺病毒载体并表达适用于疫苗开发的高抗原蛋白的快速策略
影响因子：
5
作者：
Luo, Shengxue;Zhang, Panli;Li, Tingting
通讯作者：
Li, Tingting
基于高传染性猿猴腺病毒 23 型载体的疫苗可有效保护普通狨猴免受寨卡病毒感染
影响因子：
3.8
作者：
Luo, Shengxue;Zhao, Wei;Li, Chengyao
通讯作者：
Li, Chengyao
通过一组新的两项测定确定普通狨猴中人类 5 型腺病毒中和抗体的血清阳性率
影响因子：
2.2
作者：
Wang, Qi;Sun, Yachun;Li, Tingting
通讯作者：
Li, Tingting
影响因子：
64.8
作者：
Mulligan, Mark J.;Lyke, Kirsten E.;Jansen, Kathrin U.
通讯作者：
Jansen, Kathrin U.